Drugs / Cudetaxestat
Cudetaxestat
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04939467 | Oct → Dec 2021 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04814472 | May → Aug 2021 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04814498 | May → Sep 2021 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04146805 | Jan → Dec 2020 | metabolic dysfunction-associated steatohepatitis | Blade Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05373914 | May 2022 → Dec 2023 | idiopathic pulmonary fibrosis | Blade Therapeutics | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cudetaxestat | “Cudetaxestat” NCT05373914 ↗ |
| Known as | 3-((2,6-dichloro-7-fluoro-1-(1-propyl-1h-pyrazol-4-yl)-1h-indol-3-yl)thio)-2-fluorobenzoic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802146 ↗ |
| Known as | BLD-0409 | “Cudetaxestat (BLD-0409)” NCT05373914 ↗ |
| Known as | PAT-409 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802146 ↗ |
| Modality | Small molecule | — CHEMBL4802146 ↗ |
| Route | Oral | “Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s)” NCT04146805 ↗ |